Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5708644 | 0.92 | PTGS1 (0.56) | PTGS1PTGS2 | |
| SCHEMBL5857939 | 0.91 | PTGS1 (0.64) | PTGS1PTGS2 | |
| SCHEMBL5857642 | 0.88 | PTGS1 (0.63) | PTGS1PTGS2 | |
| SCHEMBL5856620 | 0.87 | PTGS1 (0.73) | PTGS1PTGS2 | |
| SCHEMBL5856418 | 0.84 | PTGS2 (0.69) | PTGS1PTGS2 | |
| SCHEMBL5856792 | 0.84 | PTGS1 (0.63) | PTGS1PTGS2 | |
| SCHEMBL5856588 | 0.83 | PTGS1 (0.72) | PTGS1PTGS2 | |
| SCHEMBL5857487 | 0.83 | PTGS1 (0.70) | PTGS1PTGS2 | |
| SCHEMBL5858805 | 0.81 | PTGS1 (0.60) | PTGS1PTGS2 | |
| SCHEMBL5708702 | 0.81 | PTGS2 (0.49) | PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1718618-A1 | PYRAZOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER | Laboratorios del Dr. Esteve S.A. (ES) | 2006-11-08 | — | — | EP | claimed |
| WO-2005077910-A1 | PYRAZOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-08-25 | — | — | WO | claimed |
| US-20050182119-A1 | Substituted pyrazoline derivatives | LABORATORIOS DE DR. ESTEVE S.A. (ES) | 2005-08-18 | — | — | US | claimed |
| CN-1942446-A | Pyrazoline derivatives for the treatment of cancer | ESTEVE LABOR DR (ES) | 2007-04-04 | — | — | CN | disclosed |
| EP-1718618-A1 | PYRAZOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER | Laboratorios del Dr. Esteve S.A. (ES) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005077910-A1 | PYRAZOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-08-25 | — | — | WO | disclosed |
| US-20050182119-A1 | Substituted pyrazoline derivatives | LABORATORIOS DE DR. ESTEVE S.A. (ES) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182119-A1 | Substituted pyrazoline derivatives | BRCA1, KLK3, PGC | PTGS1 1109/4885PTGS2 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.